Prognostic Role of the Human Metapneumovirus (hMPV) Compared to Other Common Respiratory Viruses in Older Inpatients: a Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 1,000
- 主要终点
- Proportion of participants with death and/or organ decompensation at Day 180
研究概览
简要总结
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations.
Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases.
The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient aged 65 years or older
- •Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3,
- •Hospitalized in an Acute Medicine/Geriatrics Unit
- •Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person.
- •Affiliated to a social security scheme
排除标准
- •Refusal to participate
- •Patient deprived of liberty by a judicial or administrative decision
研究组 & 干预措施
Older patients with respiratory viral infection
Patients aged 65 years or older hospitalized in acute medicine or geriatric wards with an acute respiratory infection and a positive nasopharyngeal PCR test for a respiratory viral pathogen.
干预措施: Respiratory viral infection (Other)
结局指标
主要结局
Proportion of participants with death and/or organ decompensation at Day 180
时间窗: From baseline Day 0 to Day 180
Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.
次要结局
- Proportion of participants who died(From baseline Day 0 to Day 30, Day 180, Day 365)
- Proportion of participants with major organ decompensation(From baseline Day 0 to Day 30, Day 180, Day 365)
- Proportion of participants with unplanned hospital readmission(From baseline Day 0 to Day 30, Day 180, Day 365)
- Proportion of participants developing a lower respiratory tract infection(From baseline Day 0 to Day 30)
- Change from baseline in functional dependency assessed by ADL and/or iADL scores(Baseline Day 0, Day 30, Day 180, Day 365)
- Change from baseline in sarcopenia risk assessed by SARC-F score(Baseline Day 0, Day 30, Day 180, Day 365)
- Change from baseline in quality of life assessed by EQ-5D-3L(Baseline Day 0, Day 30, Day 180, Day 365)
- Number and type of bacterial and viral co-infections(Baseline Day 0 to D7)
- Change in respiratory viral load between Day 0 and Day 7(From Day 0 to Day 7)
- Proportion of participants with death and/or major organ decompensation at Day 30(From baseline Day 0 to Day 30)